Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan
Although fluoroquinolones are considered as alternative therapies of pulmonary Mycobacterium avium complex (MAC) disease, the association between fluoroquinolone resistance and MAC genotypes in clinical isolates from individuals not previously treated for MAC infection is not fully clear. Totals of...
Gespeichert in:
| Veröffentlicht in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019-12, Vol.25 (12), p.995-1000 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1000 |
|---|---|
| container_issue | 12 |
| container_start_page | 995 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 25 |
| creator | Yamaba, Yusuke Ito, Yutaka Suzuki, Katsuhiro Kikuchi, Toshiaki Ogawa, Kenji Fujiuchi, Satoru Hasegawa, Naoki Kurashima, Atsuyuki Higuchi, Takeshi Uchiya, Kei-ichi Watanabe, Akira Niimi, Akio |
| description | Although fluoroquinolones are considered as alternative therapies of pulmonary Mycobacterium avium complex (MAC) disease, the association between fluoroquinolone resistance and MAC genotypes in clinical isolates from individuals not previously treated for MAC infection is not fully clear.
Totals of 154 M. avium isolates and 35 Mycobacterium intracellulare isolates were obtained from treatment-naïve patients with pulmonary MAC disease at the diagnosis of MAC infection at 8 hospitals in Japan. Their susceptibilities of moxifloxacin were determined by broth microdilution methods. Moxifloxacin-resistant isolates were examined for mutations of gyrA and gyrB. Variable numbers of tandem repeats (VNTR) assay was performed using 15 M. avium VNTR loci and 16 M. intracellulare VNTR loci.
Moxifloxacin susceptibility was categorized as resistant and intermediate for 6.5% and 16.9%, respectively, of M. avium isolates and 8.6% and 17.1% of M. intracellulare isolates. Although the isolates of both species had amino acid substitutions of Thr 96 and Thr 522 at the sites corresponding to Ser 95 in the M. tuberculosis GyrA and Gly 520 in the M. tuberculosis GyrB, respectively, these substitutions were observed irrespective of susceptibility and did not confer resistance. The VNTR assays showed revealed three clusters among M. avium isolates and two clusters among M. intracellulare isolates. No significant differences in moxifloxacin resistance were observed among these clusters.
Although resistance or intermediate resistance to moxifloxacin was observed in approximately one-fourth of M. avium and M. intracellulare isolates, this resistance was not associated with mutations in gyrA and gyrB or with VNTR genotypes. |
| doi_str_mv | 10.1016/j.jiac.2019.05.028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2313359794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X19301631</els_id><sourcerecordid>2313359794</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-2f8ee4935162207f5f55cfbd3c14654a4911fd52f5c69f6d19c7cf77c5b415343</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhq0KVOjCH-ihypFLUo8_4ljqpUIFWoG4UKk3y-uMV15l42AniP33TVio1AsXjzV65tXMQ8hnoBVQqL9uq22wrmIUdEVlRVnzgZyC4KpUqqFH858LKDmDPyfkU85bSkHJpvlITjgwrkGzUzLcxefgu_hsXeiLhDnk0fYOC9u3xQb7OO6H0G-K6Iu7vYtr60ZMYdoV9unlnan_-6Efk3XYdVNnExYhx86OmOd-8csOtj8jx952Gc9f64r8vvrxcHlT3t5f_7z8fls6IeqxZL5BFJpLqBmjyksvpfPrljsQtRRWaADfSualq7WvW9BOOa-Uk2sBkgu-IheH3CHFxwnzaHYhL3vZHuOUDePAudRKLyg7oC7FnBN6M6Sws2lvgJrFtNmaxbRZTBsqzWx6Hvrymj-td9j-G3lTOwPfDgDOVz4FTCa7gLPaNiR0o2ljeC__Lyy_kXE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2313359794</pqid></control><display><type>article</type><title>Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yamaba, Yusuke ; Ito, Yutaka ; Suzuki, Katsuhiro ; Kikuchi, Toshiaki ; Ogawa, Kenji ; Fujiuchi, Satoru ; Hasegawa, Naoki ; Kurashima, Atsuyuki ; Higuchi, Takeshi ; Uchiya, Kei-ichi ; Watanabe, Akira ; Niimi, Akio</creator><creatorcontrib>Yamaba, Yusuke ; Ito, Yutaka ; Suzuki, Katsuhiro ; Kikuchi, Toshiaki ; Ogawa, Kenji ; Fujiuchi, Satoru ; Hasegawa, Naoki ; Kurashima, Atsuyuki ; Higuchi, Takeshi ; Uchiya, Kei-ichi ; Watanabe, Akira ; Niimi, Akio</creatorcontrib><description>Although fluoroquinolones are considered as alternative therapies of pulmonary Mycobacterium avium complex (MAC) disease, the association between fluoroquinolone resistance and MAC genotypes in clinical isolates from individuals not previously treated for MAC infection is not fully clear.
Totals of 154 M. avium isolates and 35 Mycobacterium intracellulare isolates were obtained from treatment-naïve patients with pulmonary MAC disease at the diagnosis of MAC infection at 8 hospitals in Japan. Their susceptibilities of moxifloxacin were determined by broth microdilution methods. Moxifloxacin-resistant isolates were examined for mutations of gyrA and gyrB. Variable numbers of tandem repeats (VNTR) assay was performed using 15 M. avium VNTR loci and 16 M. intracellulare VNTR loci.
Moxifloxacin susceptibility was categorized as resistant and intermediate for 6.5% and 16.9%, respectively, of M. avium isolates and 8.6% and 17.1% of M. intracellulare isolates. Although the isolates of both species had amino acid substitutions of Thr 96 and Thr 522 at the sites corresponding to Ser 95 in the M. tuberculosis GyrA and Gly 520 in the M. tuberculosis GyrB, respectively, these substitutions were observed irrespective of susceptibility and did not confer resistance. The VNTR assays showed revealed three clusters among M. avium isolates and two clusters among M. intracellulare isolates. No significant differences in moxifloxacin resistance were observed among these clusters.
Although resistance or intermediate resistance to moxifloxacin was observed in approximately one-fourth of M. avium and M. intracellulare isolates, this resistance was not associated with mutations in gyrA and gyrB or with VNTR genotypes.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2019.05.028</identifier><identifier>PMID: 31239192</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; DNA Gyrase - genetics ; Drug Resistance, Bacterial - genetics ; Genotype ; gyrA ; gyrB ; Humans ; Japan ; Microbial Sensitivity Tests ; Minisatellite Repeats - genetics ; Moxifloxacin ; Moxifloxacin - pharmacology ; Moxifloxacin - therapeutic use ; Mutation ; Mycobacterium avium - drug effects ; Mycobacterium avium - genetics ; Mycobacterium avium - isolation & purification ; Mycobacterium avium complex ; Mycobacterium avium Complex - drug effects ; Mycobacterium avium Complex - genetics ; Mycobacterium avium Complex - isolation & purification ; Mycobacterium avium-intracellulare Infection - drug therapy ; Mycobacterium avium-intracellulare Infection - microbiology ; Variable numbers of tandem repeats</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-12, Vol.25 (12), p.995-1000</ispartof><rights>2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><rights>Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-2f8ee4935162207f5f55cfbd3c14654a4911fd52f5c69f6d19c7cf77c5b415343</citedby><cites>FETCH-LOGICAL-c446t-2f8ee4935162207f5f55cfbd3c14654a4911fd52f5c69f6d19c7cf77c5b415343</cites><orcidid>0000-0002-1538-5551 ; 0000-0003-0717-7450 ; 0000-0001-7428-1245</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31239192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamaba, Yusuke</creatorcontrib><creatorcontrib>Ito, Yutaka</creatorcontrib><creatorcontrib>Suzuki, Katsuhiro</creatorcontrib><creatorcontrib>Kikuchi, Toshiaki</creatorcontrib><creatorcontrib>Ogawa, Kenji</creatorcontrib><creatorcontrib>Fujiuchi, Satoru</creatorcontrib><creatorcontrib>Hasegawa, Naoki</creatorcontrib><creatorcontrib>Kurashima, Atsuyuki</creatorcontrib><creatorcontrib>Higuchi, Takeshi</creatorcontrib><creatorcontrib>Uchiya, Kei-ichi</creatorcontrib><creatorcontrib>Watanabe, Akira</creatorcontrib><creatorcontrib>Niimi, Akio</creatorcontrib><title>Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><description>Although fluoroquinolones are considered as alternative therapies of pulmonary Mycobacterium avium complex (MAC) disease, the association between fluoroquinolone resistance and MAC genotypes in clinical isolates from individuals not previously treated for MAC infection is not fully clear.
Totals of 154 M. avium isolates and 35 Mycobacterium intracellulare isolates were obtained from treatment-naïve patients with pulmonary MAC disease at the diagnosis of MAC infection at 8 hospitals in Japan. Their susceptibilities of moxifloxacin were determined by broth microdilution methods. Moxifloxacin-resistant isolates were examined for mutations of gyrA and gyrB. Variable numbers of tandem repeats (VNTR) assay was performed using 15 M. avium VNTR loci and 16 M. intracellulare VNTR loci.
Moxifloxacin susceptibility was categorized as resistant and intermediate for 6.5% and 16.9%, respectively, of M. avium isolates and 8.6% and 17.1% of M. intracellulare isolates. Although the isolates of both species had amino acid substitutions of Thr 96 and Thr 522 at the sites corresponding to Ser 95 in the M. tuberculosis GyrA and Gly 520 in the M. tuberculosis GyrB, respectively, these substitutions were observed irrespective of susceptibility and did not confer resistance. The VNTR assays showed revealed three clusters among M. avium isolates and two clusters among M. intracellulare isolates. No significant differences in moxifloxacin resistance were observed among these clusters.
Although resistance or intermediate resistance to moxifloxacin was observed in approximately one-fourth of M. avium and M. intracellulare isolates, this resistance was not associated with mutations in gyrA and gyrB or with VNTR genotypes.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>DNA Gyrase - genetics</subject><subject>Drug Resistance, Bacterial - genetics</subject><subject>Genotype</subject><subject>gyrA</subject><subject>gyrB</subject><subject>Humans</subject><subject>Japan</subject><subject>Microbial Sensitivity Tests</subject><subject>Minisatellite Repeats - genetics</subject><subject>Moxifloxacin</subject><subject>Moxifloxacin - pharmacology</subject><subject>Moxifloxacin - therapeutic use</subject><subject>Mutation</subject><subject>Mycobacterium avium - drug effects</subject><subject>Mycobacterium avium - genetics</subject><subject>Mycobacterium avium - isolation & purification</subject><subject>Mycobacterium avium complex</subject><subject>Mycobacterium avium Complex - drug effects</subject><subject>Mycobacterium avium Complex - genetics</subject><subject>Mycobacterium avium Complex - isolation & purification</subject><subject>Mycobacterium avium-intracellulare Infection - drug therapy</subject><subject>Mycobacterium avium-intracellulare Infection - microbiology</subject><subject>Variable numbers of tandem repeats</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhq0KVOjCH-ihypFLUo8_4ljqpUIFWoG4UKk3y-uMV15l42AniP33TVio1AsXjzV65tXMQ8hnoBVQqL9uq22wrmIUdEVlRVnzgZyC4KpUqqFH858LKDmDPyfkU85bSkHJpvlITjgwrkGzUzLcxefgu_hsXeiLhDnk0fYOC9u3xQb7OO6H0G-K6Iu7vYtr60ZMYdoV9unlnan_-6Efk3XYdVNnExYhx86OmOd-8csOtj8jx952Gc9f64r8vvrxcHlT3t5f_7z8fls6IeqxZL5BFJpLqBmjyksvpfPrljsQtRRWaADfSualq7WvW9BOOa-Uk2sBkgu-IheH3CHFxwnzaHYhL3vZHuOUDePAudRKLyg7oC7FnBN6M6Sws2lvgJrFtNmaxbRZTBsqzWx6Hvrymj-td9j-G3lTOwPfDgDOVz4FTCa7gLPaNiR0o2ljeC__Lyy_kXE</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Yamaba, Yusuke</creator><creator>Ito, Yutaka</creator><creator>Suzuki, Katsuhiro</creator><creator>Kikuchi, Toshiaki</creator><creator>Ogawa, Kenji</creator><creator>Fujiuchi, Satoru</creator><creator>Hasegawa, Naoki</creator><creator>Kurashima, Atsuyuki</creator><creator>Higuchi, Takeshi</creator><creator>Uchiya, Kei-ichi</creator><creator>Watanabe, Akira</creator><creator>Niimi, Akio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1538-5551</orcidid><orcidid>https://orcid.org/0000-0003-0717-7450</orcidid><orcidid>https://orcid.org/0000-0001-7428-1245</orcidid></search><sort><creationdate>201912</creationdate><title>Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan</title><author>Yamaba, Yusuke ; Ito, Yutaka ; Suzuki, Katsuhiro ; Kikuchi, Toshiaki ; Ogawa, Kenji ; Fujiuchi, Satoru ; Hasegawa, Naoki ; Kurashima, Atsuyuki ; Higuchi, Takeshi ; Uchiya, Kei-ichi ; Watanabe, Akira ; Niimi, Akio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-2f8ee4935162207f5f55cfbd3c14654a4911fd52f5c69f6d19c7cf77c5b415343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>DNA Gyrase - genetics</topic><topic>Drug Resistance, Bacterial - genetics</topic><topic>Genotype</topic><topic>gyrA</topic><topic>gyrB</topic><topic>Humans</topic><topic>Japan</topic><topic>Microbial Sensitivity Tests</topic><topic>Minisatellite Repeats - genetics</topic><topic>Moxifloxacin</topic><topic>Moxifloxacin - pharmacology</topic><topic>Moxifloxacin - therapeutic use</topic><topic>Mutation</topic><topic>Mycobacterium avium - drug effects</topic><topic>Mycobacterium avium - genetics</topic><topic>Mycobacterium avium - isolation & purification</topic><topic>Mycobacterium avium complex</topic><topic>Mycobacterium avium Complex - drug effects</topic><topic>Mycobacterium avium Complex - genetics</topic><topic>Mycobacterium avium Complex - isolation & purification</topic><topic>Mycobacterium avium-intracellulare Infection - drug therapy</topic><topic>Mycobacterium avium-intracellulare Infection - microbiology</topic><topic>Variable numbers of tandem repeats</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamaba, Yusuke</creatorcontrib><creatorcontrib>Ito, Yutaka</creatorcontrib><creatorcontrib>Suzuki, Katsuhiro</creatorcontrib><creatorcontrib>Kikuchi, Toshiaki</creatorcontrib><creatorcontrib>Ogawa, Kenji</creatorcontrib><creatorcontrib>Fujiuchi, Satoru</creatorcontrib><creatorcontrib>Hasegawa, Naoki</creatorcontrib><creatorcontrib>Kurashima, Atsuyuki</creatorcontrib><creatorcontrib>Higuchi, Takeshi</creatorcontrib><creatorcontrib>Uchiya, Kei-ichi</creatorcontrib><creatorcontrib>Watanabe, Akira</creatorcontrib><creatorcontrib>Niimi, Akio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamaba, Yusuke</au><au>Ito, Yutaka</au><au>Suzuki, Katsuhiro</au><au>Kikuchi, Toshiaki</au><au>Ogawa, Kenji</au><au>Fujiuchi, Satoru</au><au>Hasegawa, Naoki</au><au>Kurashima, Atsuyuki</au><au>Higuchi, Takeshi</au><au>Uchiya, Kei-ichi</au><au>Watanabe, Akira</au><au>Niimi, Akio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><addtitle>J Infect Chemother</addtitle><date>2019-12</date><risdate>2019</risdate><volume>25</volume><issue>12</issue><spage>995</spage><epage>1000</epage><pages>995-1000</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Although fluoroquinolones are considered as alternative therapies of pulmonary Mycobacterium avium complex (MAC) disease, the association between fluoroquinolone resistance and MAC genotypes in clinical isolates from individuals not previously treated for MAC infection is not fully clear.
Totals of 154 M. avium isolates and 35 Mycobacterium intracellulare isolates were obtained from treatment-naïve patients with pulmonary MAC disease at the diagnosis of MAC infection at 8 hospitals in Japan. Their susceptibilities of moxifloxacin were determined by broth microdilution methods. Moxifloxacin-resistant isolates were examined for mutations of gyrA and gyrB. Variable numbers of tandem repeats (VNTR) assay was performed using 15 M. avium VNTR loci and 16 M. intracellulare VNTR loci.
Moxifloxacin susceptibility was categorized as resistant and intermediate for 6.5% and 16.9%, respectively, of M. avium isolates and 8.6% and 17.1% of M. intracellulare isolates. Although the isolates of both species had amino acid substitutions of Thr 96 and Thr 522 at the sites corresponding to Ser 95 in the M. tuberculosis GyrA and Gly 520 in the M. tuberculosis GyrB, respectively, these substitutions were observed irrespective of susceptibility and did not confer resistance. The VNTR assays showed revealed three clusters among M. avium isolates and two clusters among M. intracellulare isolates. No significant differences in moxifloxacin resistance were observed among these clusters.
Although resistance or intermediate resistance to moxifloxacin was observed in approximately one-fourth of M. avium and M. intracellulare isolates, this resistance was not associated with mutations in gyrA and gyrB or with VNTR genotypes.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31239192</pmid><doi>10.1016/j.jiac.2019.05.028</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1538-5551</orcidid><orcidid>https://orcid.org/0000-0003-0717-7450</orcidid><orcidid>https://orcid.org/0000-0001-7428-1245</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-12, Vol.25 (12), p.995-1000 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2313359794 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use DNA Gyrase - genetics Drug Resistance, Bacterial - genetics Genotype gyrA gyrB Humans Japan Microbial Sensitivity Tests Minisatellite Repeats - genetics Moxifloxacin Moxifloxacin - pharmacology Moxifloxacin - therapeutic use Mutation Mycobacterium avium - drug effects Mycobacterium avium - genetics Mycobacterium avium - isolation & purification Mycobacterium avium complex Mycobacterium avium Complex - drug effects Mycobacterium avium Complex - genetics Mycobacterium avium Complex - isolation & purification Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Variable numbers of tandem repeats |
| title | Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T00%3A28%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Moxifloxacin%20resistance%20and%20genotyping%20of%20Mycobacterium%20avium%20and%20Mycobacterium%20intracellulare%20isolates%20in%20Japan&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Yamaba,%20Yusuke&rft.date=2019-12&rft.volume=25&rft.issue=12&rft.spage=995&rft.epage=1000&rft.pages=995-1000&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2019.05.028&rft_dat=%3Cproquest_cross%3E2313359794%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2313359794&rft_id=info:pmid/31239192&rft_els_id=S1341321X19301631&rfr_iscdi=true |